Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | VEGFA | P15692 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.45 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30584532 | 1.00 | MEN1 (0.49) | MEN1KMT2AATMVEGFAEGLN1 | |
| SCHEMBL18291467 | 0.95 | MEN1 (0.46) | MEN1KMT2AATMVEGFAEGLN1 | |
| SCHEMBL18201812 | 0.90 | CYP3A4 (0.48) | MEN1KMT2ATBK1GPR119CHRM2 | |
| SCHEMBL20740461 | 0.89 | GPR119 (0.52) | MEN1KMT2ATBK1GPR119TP53 | |
| SCHEMBL18201816 | 0.87 | PIK3CA (0.44) | TBK1 | |
| SCHEMBL20528288 | 0.87 | CYP1A2 (0.47) | — | |
| SCHEMBL29686670 | 0.87 | PIK3CA (0.44) | TBK1 | |
| SCHEMBL30520640 | 0.86 | MEN1 (0.50) | MEN1KMT2AATMVEGFAEGLN1 | |
| SCHEMBL18191713 | 0.86 | PIK3CA (0.46) | MEN1KMT2AATMVEGFAEGLN1 | |
| SCHEMBL2933302 | 0.85 | MEN1 (0.49) | MEN1KMT2AATMVEGFAEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| US-12559485-B2 | CDK6/DYRK2 dual-target inhibitor, and preparation method therefor and use thereof | JIANGSU TASLY DIYI PHARMACEUTICAL CO. , LTD. (CN) | 2026-02-24 | — | — | US | disclosed |
| EP-4631941-A1 | BENZOTHIAZOLE PYRIMIDINEAMINE DYRK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) | 2025-10-15 | — | — | EP | disclosed |
| EP-4282864-B1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD (CN) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024173646-A1 | CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS | INNOVO THERAPEUTICS, INC. (US) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024119866-A1 | BENZOTHIAZOLE PYRIMIDINEAMINE DYRK2 INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 江苏天士力帝益药业有限公司 | 2024-06-13 | — | — | WO | disclosed |
| CN-118146213-A | Benzothiazole pyrimidine amine DYRK2 inhibitor and preparation method and application thereof | 江苏天士力帝益药业有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2024-02-08 | — | — | US | disclosed |
| EP-4282864-A1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| EP-4282864-A1 | CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) | 2023-11-29 | — | — | EP | disclosed |
| WO-2016194831-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 帝人ファーマ株式会社 | 2016-12-08 | — | — | WO | disclosed |
| WO-2016173505-A1 | CERTAIN PROTEIN KINASE INHIBITOR | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2016-11-03 | — | — | WO | disclosed |
| US-9416136-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2016-08-16 | — | — | US | disclosed |
| US-8962630-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2015-02-24 | — | — | US | disclosed |
| US-20140135312-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2014-05-15 | — | — | US | disclosed |
| EP-2379528-B1 | PROTEIN KINASE INHIBITORS | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130184285-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS (GB) | 2013-07-18 | — | — | US | disclosed |
| US-8415355-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK9, CDK6, CDK7 | MEN1 2512/4885KMT2A 915/4885ATM 364/4885 |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | MEN1 3341/4885KMT2A 1553/4885ATM 353/4885 |
| US-12559485-B2 | CDK6/DYRK2 dual-target inhibitor, and preparation method therefor and use thereof | CDK6, CDK2, CDKL1 | MEN1 1927/4885KMT2A 1445/4885ATM 440/4885 |
| US-20130184285-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | MEN1 3341/4885KMT2A 1553/4885ATM 353/4885 |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | MEN1 3341/4885KMT2A 1553/4885ATM 353/4885 |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | MEN1 3341/4885KMT2A 1553/4885ATM 353/4885 |
| US-20140135312-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | MEN1 3341/4885KMT2A 1553/4885ATM 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.